TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01908335
Drug: Pegasys /RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study: NCT00124696
Drug: Cocaethylene
Normalized name: Cocaethylene
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00182793
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study: NCT02719028
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
Study: NCT03854552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT01234142
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
Study: NCT01234142
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
Study: NCT03699774
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin is provided as a 10-mg tablet for oral administration
Study: NCT01716585
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT01716585
Drug: Placebo for ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01716585
Drug: Placebo for ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02476864
Drug: Treatment A (adult formulation)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
Study: NCT02476864
Drug: Treatment B (pediatric formulation)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
Study: NCT00405756
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Study: NCT03111810
Drug: AZD4017 and prednisolone
Normalized name: prednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
Study: NCT04077567
Drug: TS-152
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg,80mg
Study: NCT00372073
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg bid x 3 days every 2 weeks
Study: NCT02707120
Drug: PRGF-Endoret
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
Study: NCT04051320
Drug: Estradiol 2 Mg tablet
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg estradiol tablet
Study: NCT03334682
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dispensation of spironolactone at each visit according to the arm description described above.
Study: NCT03334682
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
Study: NCT02159495
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01293357
Drug: LEO 90105
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment
Study: NCT02711891
Drug: Drug, placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
Study: NCT03639493
Drug: Exforge® tab 10/160mg, Crestor® tab 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
Study: NCT03639493
Drug: CJ-30060 10/160/20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
Study: NCT02552537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
Study: NCT02189239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03429803
Drug: DAY101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 day cycle, oral, once per week
Study: NCT02242305
Drug: Hyoscine Butylbromide - Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01598831
Drug: ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study: NCT01598831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
Study: NCT01381601
Drug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Study: NCT01724021
Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: NCT01724021
Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: NCT03023436
Drug: Fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
Study: NCT00977691
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide
Study: NCT03490123
Drug: R1-Total community treatment with azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT03490123
Drug: R2-Total community treatment with azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT03490123
Drug: R3-Total community treatment with azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT03490123
Drug: R2-Total targeted treatment with azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT03490123
Drug: R3-Total targeted treatment with azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
Study: NCT02094339
Drug: opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
Study: NCT00565721
Drug: Fluciclatide Injection - (AH111585 (F18))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F labelled Cyclic RGD peptide PET agent for injection.
Study: NCT01591044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff bid or 2 puffs bid
Study: NCT01591044
Drug: R940343 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: R343 1mg, 1 puff bid
Study: NCT01591044
Drug: R940343 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: R343 2mg, 2 puffs bid
Study: NCT03950505
Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5\~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
Study: NCT03600233
Drug: CVM-1118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.
Study: NCT06745856
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
Study: NCT00286234
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: omacor placebo plus niaspan placebo
Study: NCT01634087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally
Study: NCT04003948
Drug: Ibogaine Hydrochloride
Normalized name: IBOGAINE HYDROCHLORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
Study: NCT03356327
Drug: Actitan F
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
Study: NCT03356327
Drug: Standard Oral Rehydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral rehydration as suggested by ESPGHAN guidelines
Study: NCT04118127
Drug: 2mg conventional tablet, once-weekly tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
Study: NCT02134340
Drug: [I-124]-CPD-1028 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
Study: NCT00209079
Drug: Gleevec, Taxotere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
Study: NCT01040000
Drug: NPC-1C/NEO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
Study: NCT01639846
Drug: RX-10045
Normalized name: BARRIER,SENSURA COLOPLAST #10045
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
Study: NCT00160147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03284931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04662710
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.
Study: NCT04662710
Drug: Leucovorin (or Levoleucovorin)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
Study: NCT04333537
Drug: Imaging Agent
Normalized name: NON-IMAGING AGENTS RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive imaging agent via injection
Study: NCT04630808
Drug: NCX 470 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 470 Ophthalmic Solution, 0.1%
Study: NCT02761486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in matching capsules
Study: NCT00427089
Drug: Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate
Normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L gut lavage solution
Study: NCT01839721
Drug: Bifilact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
Study: NCT02119754
Drug: Plurogel PN
Normalized name: PLUROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04553068
Drug: EVO100
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVO100 vaginal gel
Study: NCT04553068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal gel
Study: NCT01922479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Study: NCT03057314
Drug: Amorphous Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension
Study: NCT02790957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of an equal volume of NaCl solution
Study: NCT04557189
Drug: TAK-951 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-951 placebo-matching SC injection
Study: NCT00708344
Drug: Irbesartan - Hydrochlorothiazide
Normalized name: hydrochlorothiazide / irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
Study: NCT00708344
Drug: Irbesartan - Hydrochlorothiazide
Normalized name: hydrochlorothiazide / irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
Study: NCT02232620
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Study: NCT01636479
Drug: SAR405838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT04231136
Drug: EAPA115
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAPA115
Study: NCT04231136
Drug: RAPA115
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAPA115
Study: NCT00684229
Drug: general anesthesia followed by opioid analgesia
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: sevoflurane general anesthesia and postoperative opioid analgesia
Study: NCT03011320
Drug: EC1456
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) bolus dose
Study: NCT02939326
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04918524
Drug: low molecular weight heparin Enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.
Study: NCT02651311
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
Study: NCT02651311
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen in ward when more or equal to FLACC scale 4.
Study: NCT04013555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored effervescent formulation designed to mimic NAC
Study: NCT02173769
Drug: Spiriva® Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Study: NCT02173769
Drug: Striverdi® Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
Study: NCT00631514
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study: NCT00631514
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study: NCT00631514
Drug: piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Study: NCT00135031
Drug: Bifidobacterium infantis 35624
Normalized name: bifidobacterium infantis 35624
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151058
Drug: Colgate® Regular Cavity Protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
Study: NCT01010880
Drug: BKT140
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
Study: NCT01631214
Drug: Placebo to Alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet taken once a week during the double-blind treatment phase.
Study: NCT03656562
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg powder in vial for solution for injection; after reconstitution to 150 mg/mL per vial, a dose of 300 mg
Study: NCT03656562
Drug: VAY736 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection; 0 mg/mL administered as 2 mL s.c. injection
Study: NCT03656562
Drug: CFZ533
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/mL as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
Study: NCT03656562
Drug: CFZ533 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as concentrate in vial for infusion, administered at a dose of 10 mg/kg as i.v. infusion
Study: NCT03117751
Drug: Erwinase®
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be used in case of hypersensitivity or intolerance to Pegaspargase or if Pegaspargase is not available. Given IV or intramuscularly (IM).
Study: NCT03117751
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT03117751
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT03117751
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT03117751
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.